Donald E. Bobo Jr - Oct 15, 2024 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role: CVP,Strategy/Corp Development
Signature: Linda J. Park, Attorney-in-Fact
Stock symbol: EW
Transactions as of: Oct 15, 2024
Transactions value $: -$121,150
Form type: 4
Date filed: 10/15/2024, 05:03 PM
Previous filing: Sep 11, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EW	Common Stock	Options Exercise	$226K	+5K	+10.65%	$45.28	51.9K	Oct 15, 2024	Direct	F1
transaction	EW	Common Stock	Sale	-$348K	-5K	-9.63%	$69.51	46.9K	Oct 15, 2024	Direct	F1, F2
holding	EW	Common Stock						38.6K	Oct 15, 2024	401(k)
holding	EW	Common Stock						135K	Oct 15, 2024	By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EW	Employee Stock Option (Right to Acquire)	Options Exercise	$0	-5K	-10.99%	$0.00	40.5K	Oct 15, 2024	Common Stock	5K	$45.28	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023.
F2	This transaction was executed in multiple trades at prices ranging from $69.34 to $69.69. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.